Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients

Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 3, 2014, Pages 249-253

  Chen, Dawei ^a   Guo, Feng ^a   Shi, Jinxiu ^b   Zhang, Chenhui ^b   Wang, Zhaowen ^a   Fan, Junwei ^a   Peng, Zhihai ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

Author keywords

CYP3A5; Hemoglobin; Liver transplantation; NR1I3; SNP; Tacrolimus pharmacokinetics

Indexed keywords

ALBUMIN; CYTOCHROME P450 3A5; HEMOGLOBIN; TACROLIMUS; CELL RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYP3A5 GENE; DOSE RESPONSE; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NR1I3 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SURGICAL PATIENT; GENETICS; METABOLISM; MIDDLE AGED;

CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HEMOGLOBINS; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TACROLIMUS;

EID: 84903597118     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-13-RG-095     Document Type: Article

References (35)

1. Jacobson, P. A., Oetting, W. S., Brearley, A. M., Leduc, R., Guan, W., Schladt, D., Matas, A. J., Lamba, V., Julian, B. A., et al.: Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation, 91: 300-308 (2011).
2. Barry, A. and Levine, M.: A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients. Ther. Drug Monit., 32: 708-714 (2010).
3. Birdwell, K. A., Grady, B., Choi, L., Xu, H., Bian, A., Denny, J. C., Jiang, M., Vranic, G., Basford, M., et al.: The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet. Genomics, 22: 32-42 (2012).
4. Tang, H. L., Xie, H. G., Yao, Y. and Hu, Y. F.: Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet. Genomics, 21: 713-720 (2011).
5. Staatz, C. E. and Tett, S. E.: Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet., 43: 623-653 (2004).
6. Wallemacq, P., Armstrong, V. W., Brunet, M., Haufroid, V., Holt, D. W., Johnston, A., Kuypers, D., Le Meur, Y., Marquet, P., et al.: Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther. Drug Monit., 31: 139-152 (2009).
7. Wei-lin, W., Jing, J., Shu-sen, Z., Li-hua, W., Ting-bo, L., Song-feng, Y. and Sheng, Y.: Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl., 12: 775-780 (2006).
8. Zhang, X., Wang, Z., Fan, J., Liu, G. and Peng, Z.: Impact of interleukin- 10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period. Eur. J. Clin. Pharmacol., 67: 803-813 (2011).
9. Kim, I. W., Moon, Y. J., Ji, E., Kim, K. I., Han, N., Kim, S. J., Shin, W. G., Ha, J., Yoon, J. H., et al.: Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients. Eur. J. Clin. Pharmacol., 68: 657-669 (2012).
10. Shi, Y., Li, Y., Tang, J., Zhang, J., Zou, Y., Cai, B. and Wang, L.: Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene, 512: 226-231 (2013).
11. Uesugi, M., Masuda, S., Katsura, T., Oike, F., Takada, Y. and Inui, K.: Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet. Genomics, 16: 119-127 (2006).
12. Ji, E., Choi, L., Suh, K. S., Cho, J. Y., Han, N. and Oh, J. M.: Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. Transplantation, 94: 866-872 (2012).
13. Baes, M., Gulick, T., Choi, H. S., Martinoli, M. G., Simha, D. and Moore, D. D.: A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol. Cell. Biol., 14: 1544-1552 (1994).
14. Tojima, H., Kakizaki, S., Yamazaki, Y., Takizawa, D., Horiguchi, N., Sato, K. and Mori, M.: Ligand dependent hepatic gene expression profiles of nuclear receptors CAR and PXR. Toxicol. Lett., 212: 288-297 (2012).
15. Burk, O., Koch, I., Raucy, J., Hustert, E., Eichelbaum, M., Brockmoller, J., Zanger, U. M. and Wojnowski, L.: The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J. Biol. Chem., 279: 38379-38385 (2004).
16. Sissung, T. M., English, B. C., Venzon, D., Figg, W. D. and Deeken, J. F.: Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics, 11: 89-103 (2010).
17. Li, D., Zhu, J. Y., Gao, J., Wang, X., Lou, Y. Q. and Zhang, G. L.: Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Clin. Chim. Acta, 383: 133-139 (2007).
18. Nebert, D. W., Zhang, G. and Vesell, E. S.: From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab. Rev., 40: 187-224 (2008).
19. Yu, X., Xie, H., Wei, B., Zhang, M., Wang, W., Wu, J., Yan, S., Zheng, S. and Zhou, L.: Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients. PLoS ONE, 6: e25933 (2011).
20. Klein, T. E., Altman, R. B., Eriksson, N., Gage, B. F., Kimmel, S. E., Lee, M. T., Limdi, N. A., Page, D., Roden, D. M., et al.: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med., 360: 753-764 (2009).
21. Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 27: 383-391 (2001).
22. Rojas, L. E., Herrero, M. J., Boso, V., Garcia-Eliz, M., Poveda, J. L., Librero, J. and Alino, S. F.: Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation. Pharmacogenet. Genomics, 23: 509-517 (2013).
23. Chen, S. Y., Li, J. L., Meng, F. H., Wang, X. D., Liu, T., Li, J., Liu, L. S., Fu, Q., Huang, M., et al.: Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism-a prospective, randomized, controlled study. Clin. Transplant., 27: E272-E281 (2013).
24. Thervet, E., Loriot, M. A., Barbier, S., Buchler, M., Ficheux, M., Choukroun, G., Toupance, O., Touchard, G., Alberti, C., et al.: Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther., 87: 721-726 (2010).
25. Handschin, C. and Meyer, U. A.: Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev., 55: 649-673 (2003).
26. Swales, K. and Negishi, M.: CAR, driving into the future. Mol. Endocrinol., 18: 1589-1598 (2004).
27. Lamba, J. K.: Pharmacogenetics of the constitutive androstane receptor. Pharmacogenomics, 9: 71-83 (2008).
28. Xu, Z. and Taylor, J. A.: SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res., 37: W600-605 (2009).
29. Barraclough, K. A., Isbel, N. M., Lee, K. J., Bergmann, T. K., Johnson, D. W., McWhinney, B. C., Ungerer, J. P., Campbell, S. B., Leary, D. R., et al.: NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation. Transplantation, 94: 1025-1032 (2012).
30. Press, R. R., Ploeger, B. A., den Hartigh, J., van der Straaten, T., van Pelt, J., Danhof, M., de Fijter, J. W. and Guchelaar, H. J.: Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther. Drug Monit., 31: 187-197 (2009).
31. Benkali, K., Premaud, A., Picard, N., Rerolle, J. P., Toupance, O., Hoizey, G., Turcant, A., Villemain, F., Le Meur, Y., et al.: Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin. Pharmacokinet., 48: 805-816 (2009).
32. Gijsen, V., Mital, S., van Schaik, R. H., Soldin, O. P., Soldin, S. J., van der Heiden, I. P., Nulman, I., Koren, G. and de Wildt, S. N.: Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J. Heart Lung Transplant., 30: 1352-1359 (2011).
33. Stratta, P., Quaglia, M., Cena, T., Antoniotti, R., Fenoglio, R., Menegotto, A., Ferrante, D., Genazzani, A., Terrazzino, S., et al.: The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. Eur. J. Clin. Pharmacol., 68: 671-680 (2012).
34. Han, N., Yun, H. Y., Hong, J. Y., Kim, I. W., Ji, E., Hong, S. H., Kim, Y. S., Ha, J., Shin, W. G., et al.: Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur. J. Clin. Pharmacol., 69: 53-63 (2013).
35. Beysens, A. J., Wijnen, R. M., Beuman, G. H., van der Heyden, J., Kootstra, G. and van As, H.: FK 506: monitoring in plasma or in whole blood? Transplant. Proc., 23: 2745-2747 (1991).